Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

SciClone Pharmaceuticals Inc (NASDAQ:SCLN)

7.79
Delayed Data
As of Aug 28
 +0.01 / +0.13%
Today’s Change
6.56
Today|||52-Week Range
11.71
-11.07%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$391.5M

Company Description

SciClone Pharmaceuticals, Inc. is a specialty pharmaceutical company with a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders. The company operates its business through two segments: China and Rest of the World including United States. Its ZADAXIN product is approved in over 30 countries and used for the treatment of hepatitis B (HBV), hepatitis C (HCV), as a vaccine adjuvant, and certain cancers. SciClone Pharmaceuticals was founded in 1990 and is headquartered in Foster City, CA.

Contact Information

SciClone Pharmaceuticals, Inc.
950 Tower Lane
Foster City California 94404-2125
P:(650) 358-3456
Investor Relations:
(650) 358-1447

Employees

Shareholders

Other institutional45.85%
Mutual fund holders36.86%
Individual stakeholders16.02%

Top Executives

Friedhelm BlobelPresident, Chief Executive Officer & Director
Wai-Shun Wilson CheungChief Financial Officer & Senior Vice President
Charles MengVice President-Compliance & General Counsel
Robert S. KingVice President-Product Development & Manufacturing
Lan XieChief Financial Officer-China Operations